Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
28.84
+0.06 (0.21%)
At close: Oct 29, 2026, 4:00 PM EDT
28.20
-0.64 (-2.22%)
After-hours: Oct 29, 2026, 7:56 PM EDT
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $490.00K in the quarter ending June 30, 2026, a decrease of -94.21%. This brings the company's total for the last twelve months to $156.04M, up 158.88% year-over-year. In the year 2025, Beam Therapeutics had annual revenue of $139.74M with 120.01% growth. That makes Beam Therapeutics the 19,297th largest company in the world by revenue and 3,027th in the United States.
Revenue (ttm)
$156.04M
Revenue Growth
+158.88%
P/S Ratio
18.47
Revenue / Employee
$288,954
Employees
540
Market Cap
2.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 139.74M | 76.23M | 120.01% |
| Dec 31, 2024 | 63.52M | -314.19M | -83.18% |
| Dec 31, 2023 | 377.71M | 316.79M | 520.01% |
| Dec 31, 2022 | 60.92M | 9.08M | 17.51% |
| Dec 31, 2021 | 51.84M | 51.82M | 215,916.67% |
| Dec 31, 2020 | 24.00K | 6.00K | 33.33% |
| Dec 31, 2019 | 18.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.68B |
| ADMA Biologics | 512.28M |
| Zai Lab | 449.61M |
| Aurinia Pharmaceuticals | 311.51M |
| Arcus Biosciences | 117.00M |
| Recursion Pharmaceuticals | 54.86M |
| NewAmsterdam Pharma Company | 7.12M |
| Celldex Therapeutics | 158.00K |
BEAM News
- 15 hours ago - Beam Therapeutics price target raised to $79 from $78 at Canaccord - TheFly
- 2 days ago - H.C. Wainwright says Beam Therapeutics data strengthens confidence - TheFly
- 2 days ago - Beam Therapeutics Transcript: Study result - Transcripts
- 2 days ago - Beam Therapeutics Press release: Study result - Filings
- 2 days ago - Beam Therapeutics Slides: Study result - Filings
- 2 days ago - Beam Therapeutics reports initial data from BEAM-301 trial - TheFly
- 2 days ago - Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress - GlobeNewsWire
- 16 days ago - Beam Therapeutics to present initial BEAM-301 data at ESGCT - TheFly